StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
SEED

Origin Agritech Limited

SEED Nasdaq Agricultural Production-Crops EDGAR ↗
$0.93
+0.02 +2.42%

Key statistics

from XBRL data in SEC filings
Market cap ⓘ
$11.1M
Revenue (TTM) ⓘ
$12.8M
Net income (TTM) ⓘ
-$7.51M
EPS (TTM) ⓘ
$-1.00
P/E ratio ⓘ
—
Dividend yield ⓘ
—
Free cash flow ⓘ
-$4.79M
Cash ⓘ
$2.23M
Total assets ⓘ
$14.2M
Gross margin ⓘ
7.0%
52-week range ⓘ
$0.87 – $2.49

AI briefing

from the latest 10-K, 10-Q and 8-K events

Origin Agritech LTD is a Chinese seed company focused on crop breeding and biotechnology, listed on NASDAQ.

What they do

Origin Agritech, through its PRC operating companies, develops and commercializes crop seeds, primarily in China. The company operates in agricultural production-crops, with subsidiaries across multiple Chinese provinces including Hubei, Anhui, Shandong, Hainan, Xinjiang, Jiangsu, and Henan. It also has a U.S.-based subsidiary, OAL SMY Corporation, and a Hong Kong entity formed in 2024.

Revenue drivers

  • Seed sales in China — Primary revenue source; fiscal 2025 revenue was $12.8 million, down from $16.2 million in 2024.
  • Geographic subsidiaries — Revenue generated through multiple regional subsidiaries across China, each contributing to overall seed sales.
  • Biotechnology and breeding — The company’s R&D in crop breeding and biotechnology supports seed product offerings, though specific segment breakdowns are not provided.

Recent performance

In fiscal 2025 (ended September 30, 2025), revenue fell to $12.8 million from $16.2 million in 2024. Net income swung to a loss of $7.5 million from a profit of $3.0 million in 2024. Diluted EPS was -$1.00 versus +$0.46 in the prior year. Operating cash flow remained negative at -$3.2 million. As of September 30, 2025, total assets were $14.2 million, total liabilities $22.8 million, and shareholder equity was -$3.3 million, with cash of $2.2 million.

Strategy

Management has not provided explicit strategic statements in the provided excerpts. The company formed a new subsidiary, Aoyu Sanya, in June 2024 and a Hong Kong entity in October 2024, indicating expansion into new regions. It continues to operate a research and development center in Beijing, suggesting ongoing investment in breeding technology. The focus appears to be on leveraging its biotechnology capabilities and expanding its geographic footprint across China and Hong Kong.

Risks

  • Negative shareholder equity — As of September 30, 2025, shareholder equity was -$3.3 million, indicating liabilities exceed assets.
  • Revenue decline — Fiscal 2025 revenue dropped 21% year-over-year from $16.2 million to $12.8 million.
  • Operating cash flow negative — Operating cash flow has been negative in three of the last five years, including -$3.2 million in 2025.
  • Going concern risk — With cash of only $2.2 million and negative equity, the company may face liquidity challenges.

Outlook

Management's forward-looking statements are not detailed in the provided excerpts. Given recent formation of subsidiaries in Hainan and Hong Kong, the company may be seeking to expand operations. However, the financial condition suggests potential challenges in sustaining operations without additional funding or improved sales.